Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant depression
A team of experts from the Icahn School of Medicine at Mount Sinai has become the first in the United States to perform a deep brain stimulation (DBS) implantation procedure as part of a multi-site, randomized controlled trial to investigate the use of healthcare company Abbott’s DBS systems for treatment-resistant depression.